Compare NWN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWN | SNDX |
|---|---|---|
| Founded | 1859 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2018 | 2014 |
| Metric | NWN | SNDX |
|---|---|---|
| Price | $52.39 | $24.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $52.50 | ★ $84.17 |
| AVG Volume (30 Days) | 273.4K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | ★ 36.45 | 11.56 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,289,363,000.00 | $172,352,000.00 |
| Revenue This Year | $8.97 | $112.05 |
| Revenue Next Year | $4.27 | $51.24 |
| P/E Ratio | $18.55 | ★ N/A |
| Revenue Growth | 11.83 | ★ 627.84 |
| 52 Week Low | $38.94 | $8.59 |
| 52 Week High | $53.66 | $25.44 |
| Indicator | NWN | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 64.33 |
| Support Level | $45.72 | $19.46 |
| Resistance Level | $53.61 | $25.16 |
| Average True Range (ATR) | 1.24 | 1.09 |
| MACD | -0.15 | 0.04 |
| Stochastic Oscillator | 61.26 | 70.05 |
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.